Investigation of Three Biomarkers for the Detection of Prostate Cancer

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Primary completion date changed from estimate of Jan 7, 2026 to Aug 7, 2025
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description revised
    • Site details revised
    • Publications: details revised at 5 of 5 entries
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Nov 2025 to Jan 7, 2026
    • Study completion date: Nov 2025 to Mar 7, 2026
    • Start date changed from estimate of Oct 2024 to Jan 7, 2025
  3. Primary and study completion dates: Oct 2025 to Nov 2025
    • Start date: Sep 2024 to Oct 2024
    v3
  4. Study Status, Eligibility, Document Sectionv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore biomarkers with PSA (prostate specific antigen). The results from this study will be used to identify the most suitable biomarker/biomarkers for use in developing a GlycoScore test. This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.
Trial Details
NCT Number NCT06554587
Lead Sponsor Medtechtomarket Consulting Ltd
Collaborators: GlycoscoreDx Ltd
Conditions
(from sponsor)		 Cancer of Prostate
Related terms Prostatic Neoplasms
Enrollment 137 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov